Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals

Viruses. 2022 Jul 19;14(7):1570. doi: 10.3390/v14071570.

Abstract

Omicron BA.1 variant can readily infect people with vaccine-induced or naturally acquired SARS-CoV-2 immunity facilitated by escape from neutralizing antibodies. In contrast, T-cell reactivity against the Omicron BA.1 variant seems relatively well preserved. Here, we studied the preexisting T cells elicited by either vaccination with the mRNA-based BNT162b2 vaccine or by natural infection with ancestral SARS-CoV-2 for their cross-reactive potential to 20 selected CD4+ T-cell epitopes of spike-protein-harboring Omicron BA.1 mutations. Although the overall memory CD4+ T-cell responses primed by the ancestral spike protein was still preserved generally, we show here that there is also a clear loss of memory CD4+ T-cell cross-reactivity to immunodominant epitopes across the spike protein due to Omicron BA.1 mutations. Complete or partial loss of preexisting T-cell responsiveness was observed against 60% of 20 nonconserved CD4+ T-cell epitopes predicted to be presented by a broad set of common HLA class II alleles. Monitoring such mutations in circulating strains helps predict which virus variants may escape previously induced cellular immunity and could be of concern.

Keywords: CD4+ T-cell epitopes; HLA motif prediction; Omicron BA.1 variant; SARS-CoV-2; T-cell response; cross-reactivity; immune escape; mutations; natural infection; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Epitopes, T-Lymphocyte / genetics
  • Humans
  • Membrane Glycoproteins
  • Mutation
  • SARS-CoV-2* / genetics
  • Spike Glycoprotein, Coronavirus* / genetics
  • T-Lymphocytes* / immunology
  • Viral Envelope Proteins / genetics

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Epitopes, T-Lymphocyte
  • Membrane Glycoproteins
  • Spike Glycoprotein, Coronavirus
  • Viral Envelope Proteins
  • spike protein, SARS-CoV-2
  • BNT162 Vaccine

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This work was supported by the Dutch Ministry of Health, Welfare, and Sport.